Table 3.
Analysis of the polymorphisms for progression-free survival (PFS) and overall survival (OS).
| PFS | OS | |||
|---|---|---|---|---|
| Median Months (95% CI) |
p-Value | Median Months (95% CI) |
p-Value | |
| VEGF rs2010963 | ||||
| G/G | 7.6 (4.8–10.4) | 0.600 | 35.4 (11.6–59.2) | 0.811 |
| G/C | 9.6 (5.9–13.2) | 22.5 (21.5–47.6) | ||
| C/C | 8.9 (7.1–10.7) | 16.9 (15–18.8) | ||
| VEGF rs1570360 | 0.554 | 0.074 | ||
| G/G | 8.9 (6.9–10.9) | 27.8 (20–35.6) | ||
| G/A | 12.6 (1.6–23.6) | 43.2 (33.2–53.2) | ||
| A/A | 9.3 (3.7–18.9) | 39.2 (12.4–65.9) | ||
| VEGF rs699947 | ||||
| C/C | 8.1 (5.3–10.9) | 0.006 | 16.9 (12.8–20.9) | 0.043 |
| C/A | N/A | N/A | ||
| A/A | 32.6 (13.2–44.9) | 59.4 (33.3–70.7) | ||
| ICAM rs5498 | ||||
| A/A | 8.9 (6.6–11.2) | 0.700 | 16.9 (12.6–21.2) | 0.159 |
| A/G | 8.1 (4.8–11.4) | 35.4 (11.2–59.5) | ||
| G/G | 9.4 (4.6–14.2) | 47.9 (26.5–85.7) | ||
| ICAM rs1799969 | ||||
| G/G | 9.1 (7–11.2) | 0.938 | 29.1 (21.4–36.9) | 0.036 |
| G/A | 8.1 (3.5–12.7) | 48.7 (34.5–62.8) | ||
| A/A | N/A | N/A | ||
| KRAS rs61764370 | ||||
| Wild type | 8.9 (3.9–13.8) | 0.880 | 43.5 (29–57.7) | 0.511 |
| Mutant | 8.1 (5.6–10.7) | 20.8 (13.9–27.7) | ||
| NRAS rs11554290 | ||||
| Wild type | 8.9 (6.2–11.6) | 0.783 | 25 (19.2–30.9) | 0.374 |
| Mutant | 8.1 (5.3–10.9) | 33.7 (19.2–30.9) | ||
| BRAF rs113488022 | ||||
| Wild type | 7.1 (6.8–7.4) | 0.466 | 16.7 (14.3–19.1) | 0.027 |
| Mutant | 5.6 (3.9–13.4) | 6.8 (4.6–15.9) | ||